These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35291847)

  • 21. Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
    Zhang ZH; Lian XY; Yao DM; He PF; Ma JC; Xu ZJ; Guo H; Zhang W; Lin J; Qian J
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1853-1864. PubMed ID: 28470473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [GUIDELINES FOR DIAGNOSIS AND TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME].
    Šimec NG; Kaić G; Škrtić A; Šiftar Z; Lasan-Trčić R; Valković T; Puškarić BJ; Rogulj IM; Zatezalo V; Nemet D; Kolonić SO
    Lijec Vjesn; 2017; 139(1-2):1-11. PubMed ID: 30148578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
    Randall MP; DeZern AE
    Cancer J; 2023 May-Jun 01; 29(3):152-159. PubMed ID: 37195771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Chua CC; Fleming S; Wei AH
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):3-12. PubMed ID: 30927972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1 signaling and inhibition in AML and MDS.
    Haroun F; Solola SA; Nassereddine S; Tabbara I
    Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
    Marques FK; Sabino AP
    Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C; Chi J; Wang L
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome.
    Choi Y; Kim SD; Park YH; Lee JS; Kim DY; Lee JH; Lee KH; Seol M; Lee YS; Kang YA; Jeon M; Jung AR; Lee JH
    Acta Haematol; 2015; 133(2):183-92. PubMed ID: 25323649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transplant for MDS: challenges and emerging strategies.
    Tamari R; Castro-Malaspina H
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelodysplastic syndromes: clinical practice guidelines in oncology.
    Greenberg PL; Attar E; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; Frankfurt O; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; O'Donnell MR; Shami PJ; Stein BL; Stone RM; Thompson JE; Westervelt P; Wheeler B; Shead DA; Naganuma M
    J Natl Compr Canc Netw; 2013 Jul; 11(7):838-74. PubMed ID: 23847220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic syndromes.
    Li H; Hu F; Gale RP; Sekeres MA; Liang Y
    Nat Rev Dis Primers; 2022 Nov; 8(1):74. PubMed ID: 36396662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
    Kanda Y
    Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinic Outcome of Allogeneic Stem Cell Transplantation in 45 Patients with MDS].
    Wang LJ; Liu MJ; Zhao XL; Ding J; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):502-9. PubMed ID: 27151019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.